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The mathematical model for the dynamics of the hepatitis C proposed in Avenda˜ no et al. (2002), with four populations (healthy
and unhealthy hepatocytes, the viral load of the hepatitis C virus, and T killer cells), is revised. Showing that the reduced
model obtained by considering only the ﬁrst three of these populations, known as basic model, has two possible equilibrium
states: the uninfected one where viruses are not present in the individual, and the endemic one where viruses and infected
cells are present. A threshold parameter (the basic reproductive virus number) is introduced, and in terms of it, the global
stability of both two possible equilibrium states is established. Other central result consists in showing, by model numerical
simulations, the feasibility of monitoring liver damage caused by HCV, avoiding unnecessary biopsies and the undesirable related
inconveniences/imponderablestothepatient;anotherresultgivesamathematicalmodellingbasistorecentlydevelopedtechniques
for the disease assessment based essentially on viral load measurements.
1.Introduction
Hepatitis C virus (HCV) infection represents a serious
problem of public health with strong clinical and eco-
nomic repercussions. Lethal consequences may arise from
a subclinical acute infection followed by a latent period,
and eventually hepatic cirrhosis (from 20% to 30% of the
cases) or to hepatocellular carcinoma (with a far smaller
percentage) [1], as ﬁnal events at the end stage of chronic
liver disease. It was not before 1989, that the infectious
viral agent was identiﬁed as HCV in patients with hepatitis
not A and not B [2]. At present, six diﬀerent genotypes of
HCV have been identiﬁed with diverse biological and clinical
behaviors. For instance, it has been observed that genotype 1
response to therapy is less eﬀective than one by genotypes 2
and 3 [3].
The most frequent ways for HCV transmission are
blood transfusion, use of intravenous drugs, hemodialysis,
tattoos, high-risk sexual behavior, occupational exposition
of medical and paramedical personnel, vertical transmission
from mother to her product, and organ transplants from an
infected donor. It is important to say that the mechanism
for HCV transmission is unidentiﬁed in a high percentage
of patients (from 20% to 40%) [4].
The incubation period of HCV is 50 days in average,
ranging from 15 to 150 days [2]. Factors inﬂuencing the
rate of progression from chronic hepatitis to cirrhosis appear
to include age at time of exposure, duration of infection,
degree of previous liver damage, immunological system
status, and HCV genotype. The disease progression is insid-
ious; the clinically signiﬁcant time of evolution varies: the
diagnosis of chronic hepatitis, cirrhosis, and hepatocellular
carcinoma have been estimated to be 10, 20, and 30 years,
respectively [1, 5]. The majority of patients show increased
levels of aminotransferases as well as hepatocellular damage.
Bleeding of esophageal varices, ascitis, coagulopathy, and2 Computational and Mathematical Methods in Medicine
encephalopathy, among others, may be observed at advanced
stages of the evolution. The progression of the disease is
variable, not always orderly nor sequential. Patients can
evolve from chronic hepatitis directly to hepatocellular
carcinomawithoutﬁrstdevelopingcirrhosis,especiallythose
with genotype 1b [5].
The mechanisms of replication and persistence of the
HCV at the cellular level have not been completely charac-
terized yet.Nevertheless,it iswellknown thatit takesplaceat
hepaticlevel,andnoreplicationatextrahepaticsiteshasbeen
reported up to date. Due to the high mutation rate of HCV,
a great amount of diﬀerent immunological variants appear;
this variance partly explains the virus ability to evade the
host’s immunological control, and the infection eventually
becomes a chronic disease in most cases. Furthermore, the
strong mutagenesis of the virus makes it very diﬃcult to
develop an eﬀective vaccine.
Nowadays,chronichepatitisCtherapyapprovedbyboth,
the Food and Drug Administration (FDA) and the European
Medicines Agency (EMEA), consists of the administration of
α − 2a or α − 2b pegylated interferon plus ribavirin [6, 7]. It
is important to observe that central goal of the treatment is
to substantially decrease the viral load [8–10].
The treatment for an HCV-infected patient essentially
depends on the degree of his/her hepatic damage. Percuta-
neousliverbiopsyisaninvasivetoolthathasbeenextensively
used to assess the degree of hepatic damage, despite having
serious inconveniences. This poses a relevant problem with
signiﬁcant impact on medicine to propose a noninvasive
procedure for monitoring the hepatic damage.
In the next section we discuss the use, importance,
and inconveniences of the percutaneous liver biopsy. In
Section 3 we present a model of four populations (healthy
and unhealthy hepatocyte, viral load, and T-killer cells),
originally proposed by Avenda˜ no et al. [11]. In Section 4,
following Avenda˜ no, we develop the qualitative analysis of
the reduced model to the ﬁrst three populations above
mentioned. In Section 5, we show that the evolution of
healthy and unhealthy hepatocyte populations and viral load
for both models of three and four populations, is practically
the same. In Section 6, we present the main result of this
research. We show that numerical estimation of parameters
in the reduced model for hepatitis C disease dynamics, using
only a suﬃcient number of viral load measurements and
a reasonable proposal for the initial value for populations,
provides us the bases for a noninvasive technique to asses the
hepatic damage. Finally, in Section 7 we discuss the results
and theirs implications.
2. Liver Biopsies and Motivation for
anAlternative
The clinical study of a patient starts when his/her infection
status is detected by using a serological HCV antibodies test.
In HCV positive patient, viral load should be quantiﬁed
in order to establish the intensity of viral replication.
Then identiﬁcation of the HCV genotype is performed by
molecular procedures in those patients with detectable viral
load; this is necessary to deﬁne duration of the therapy and
for prognostic purposes. Finally, liver biopsy is done, usually
by a percutaneous puncture, to measure the degree and
extent of liver tissue damage.
Percutaneous liver biopsy is an invasive method that had
been used extensively to evaluate the degree (intensity of
necroinﬂammatory activity), and the stage (extent of ﬁbrosis
or the presence of cirrhosis) of hepatic injury. This method
consists in the extraction of a small piece of hepatic tissue by
the insertion of a needle into the liver, which provides useful
information to classify the patient according to the stage of
the disease. Hepatic biopsy had been considered the best
available tool for diagnosing and evaluating the treatment
eﬃcacy [12]; however, it could be risky, and even produce
pain andtemporal disability tothe patient [13].Ontheother
hand, since tissue samples obtained by this method are very
small, it is debatable if they are representative of the whole
liver status [14–16].
Duetoitsinconsistenciesandinconveniences(someseri-
ous),theusefulnessoftheliverbiopsyispresentlyconsidered
less important than before; some of its questionable points
a r ea sf o l l o w s .( i )Tissue representativeness: a r et i s s u es a m p l e s
obtained by percutaneous liver biopsies really representative
of the whole liver? (ii) Finding reproductiveness. The ﬁndings
by diﬀerent pathologists or from diﬀerent samples could
vary remarkably either in minor or major degree, and such
diﬀerences seem to be the rule, not the exception. (iii)
Biopsy usefulness: the most important point is that biopsies
were considered useful in classifying patients according to
the stage of the disease, and identifying patients that had
already developed cirrhosis. In both proposals, biopsies do
n o ts e e mt ob er e a l l yu s e f u la ta l l .( i v )Biopsy futility: given
the satisfactory response to therapy in patients infected by
genotypes 2 or 3, biopsy is considered unnecessary. With
regard to genotype 1 or 4, who only responds in 50% of the
cases, performing a biopsy is still under debate [3].
The fear, pain, and the temporary disability of the
patient, are considered as serious and negative aspects.
Nonetheless, liver biopsy is still mandatory to assess the
stage and degree of liver disease. Alternatively, nowadays we
dispose of a new method to evaluate the status of the liver
tissue, in particular the stage of ﬁbrosis, named elastography
(Fibroscan), which has only recently been introduced in
clinical practice and is not yet available in low income
countries/areas.
In addition to the panel of blood markers, are in progress
another noninvasive tool for the evaluation of the extent
of ﬁbrosis [17]. These markers are useful for establishing
the two ends of ﬁbrosis spectrum (minimal ﬁbrosis and
cirrhosis) but are less helpful in assessing its mid ranges. In
particular, the elastography is improved when it is combined
with markers (for details, see [3]).
In the last years, the viral load count has been used as a
noninvasive technique that provides useful information on
the intensity of the viral replication, making unnecessary the
performance of liver biopsy depending on its viral genotype
[3]. This technique is very reliable and also has been used
to compare the infection degree before and after a particular
treatment has been decided.Computational and Mathematical Methods in Medicine 3
3. Dynamicsof the HepatitisC: Model I
In this section, for completeness, we present a brief recapitu-
lation of the original model for the dynamics of the hepatitis
Cp r o p o s e di n[ 11], with special attention on those aspects
with relevance to our research objectives. The model is given
by the following system of ordinary diﬀerential equations
(ODE):
˙ Hs = βs − kHsV −μsHs,
˙ Hi = kHsV −δHiT −μiHi,
˙ V = pHi −μVV,
˙ T = βT
 
1 −
T
Tmax
 
V −μTT,
(1)
where Hs(t) is the healthy liver cell population at time t,
assuming that these cells are reproduced at the constant rate
βs and die with a per capita rate μs,w h e r e a sHi(t) is the
infected liver cell population at time t. The healthy liver cells
are infected at a rate proportional to the product of Hs and
V, with a proportionality constant k, and the infected ones
dying with a per capita rate μi. V(t) is the HCV viral load at
time t. Hepatitis C virions are produced by the infected cells
at rate of p virions per infected cell per day. On the other
hand, viruses die with a per capita constant rate μV. T(t)i s
the population of the T killer cells (CD8+ cytotoxic cells) at
time t. These cells kill infected ones at a rate proportional
to the product of Hi and T, with a proportionality constant
δ. In the presence of HCV, the T killer cells reproduction
is proportional to the viral load V with a saturation rate
βT(1 − T/Tmax), where βT is the T cell growth rate, and
Tmax is the possible maximum level of the T cell population.
Furthermore, T cells die at a per capita constant rate μT.
Note the region
Ω =
⎧
⎪ ⎨
⎪ ⎩
(Hs,Hi,V,T) ∈ R4
+
             
0 ≤ Hs ≤ HM,0 ≤ Hi ≤ HM
Hs +Hi ≤ HM,0 ≤ V ≤ VM
0 ≤ T ≤ TM
⎫
⎪ ⎬
⎪ ⎭
,
(2)
where HM = βs/μs, VM = (p/μV)HM, TM = (βT/μ
∗
T)VM,a n d
μ
∗
T = μT +( βT/Tmax)VM is positively invariant subset for
system (1). That is, every solution path of this system with
initial conditions in Ω will remain in Ω for all future time.
The value of the threshold parameter
R0 =
kpβs
μiμsμV
(3)
which is named basic reproductive virus number, plays a
central role in the analysis of qualitative global behavior of
solutions of the system (1) (i.e., the disease evolution to the
cure, or either to the chronic illness), clearly with relevant
implications for the treatment of the hepatitis C.
The central results are as follows.
(1) If R0 ≤ 1, then the system (1)h a so n eo n l y
admissible equilibrium state in Ω, the trivial one I0 =
(βs/μs,0,0,0), which is globally asymptotically stable.
The model predicts that without importing the
intensity of the infection (i.e., except that the value of
V0 ≤ VM), the infected individual, eventually, always
will be healthy.
(2) If R0 > 1, then the system (1) has two admissible
equilibrium states:
(i) the trivial one I0 = (βs/μs,0,0,0),whichisnow
unstable;
(ii) the endemic one (V∗ > 0)
I1 =
 
βs
kV∗ +μs
,
μVV∗
p
,V
∗,
βTTmaxV∗
βTV∗ +μTTmax
 
(4)
which is globally asymptotically stable and that
corresponds to the endemic patient of hepatitis
C. Furthermore, I1 ∈ int(Ω)i fμi >μ s.
Finally, it is very important to observe that the parame-
ters related to the immune response (i.e., to T killer cells) are
not present in the threshold parameter R0. For this reason, in
the following we restrain our study to basic model with only
three populations (healthy and unhealthy hepatocytes, and
the viral load of the HCV).
4.Dynamicsofthe HepatitisC:ReducedModel
Asitwasjustmentionedabove,onlysixofthetenparameters
in the model (1) are present in the threshold parameter R0.
On the other hand, it is well known that immunological
response, in principle, is ineﬃcient in the presence of HCV
infection. Then, in the following, T killer cell population
will not be considered. So, the model (1) is reduced to the
following one:
˙ Hs = βs −kHsV −μsHs,
˙ He = kHsV −μeHe,
˙ V = pHe −μVV.
(5)
This basic model for that hepatitis C dynamics has been
reported by [9, 18–21], among others. All parameters in the
model are positive. It is a simple matter to verify that any
initial value problem for the diﬀerential equations system
(5) satisfy the locally existence and uniqueness theorem
conditions.
As in [11], we begin with regarding the set
Ω=
 
(Hs,He,V)∈R3
+
         
0≤Hs≤HM,0 ≤He≤HM,
Hs+He≤HM,0 ≤V ≤VM
 
,( 6 )
where HM = βs/μs and VM = (p/μV)HM (see Figure 1).
Here, HM is the possible maximum size of the population
of healthy hepatocyte in the liver of a healthy individual,
and VM is the virion maximum quantity produced by all
hepatocytes during their whole lifespan (i.e., it is the viral
maximum load that can be support by an individual).4 Computational and Mathematical Methods in Medicine
V
Hs
(0,HM,0)
Ω
He
(0,0,VM)
I0 = (HM,0,0)
Figure 1: Set Ω is positive invariant.
Lemma 1. If μe ≥ μs, then Ω is a positive invariant subset of
R3
+ for the system (5).
Proof. It is direct to verify that the vector ﬁeld deﬁned by
the system (5) does not point to the exterior of Ω,o ni t s
boundary ∂Ω.
4.1. Equilibrium States. In this section, we show that the
system (5) has, at most, two possible equilibrium states.
One of them has no viruses present and corresponds to the
uninfected equilibrium state (i.e., to the healthy individual),
and another one has a positive constant virus load and
corresponds to the endemically infected equilibrium state
(i.e., to the chronic illness).
The equilibrium states of the system (5) are obtained for
solving the algebraic equation system:
0 = βs −kHsV −μsHs,
0 = kHsV −μeHe,
0 = pHe − μVV.
(7)
For a given V∗, from the third equation of (7), it follows
that
H
∗
e =
μV
p
V
∗. (8)
And from the ﬁrst equation of (7), we have
H
∗
s =
βs
μs +kV∗. (9)
Substituting(9)and(8)inthesecondequationof (7),we
obtain
 
pkβs − μsμeμV −kμeμVV∗ 
V∗ = 0. (10)
If V∗ = 0, from (8)a n d( 9), then it follows that H∗
e = 0
and H∗
s = βs/μs. Therefore,
I0 =
 
βs
μs
,0,0
 
(11)
is a state of equilibrium of (5). This state corresponds to
the healthy or not infected individual. In consequence, all
the hepatic cells are healthy, and H∗
s = βs/μs is the average
maximumnumberofcellsintheliverofahealthyindividual.
For V∗ > 0, from (10), one obtains that:
V∗ =
μs
k
(R0 − 1), (12)
where
R0 =
kpβs
μeμsμV
(13)
is the same threshold parameter introduced in [11].
Obviously, V∗ > 0 if and only if R0 > 1.
Substituting V∗ given by (12)i n( 8)a n d( 9), it follows
that
H
∗
e =
βs
μeR0
(R0 −1), H
∗
s =
βs
μsR0
. (14)
Therefore, the second equilibrium state of the system (5)
is
I1 =
 
βs
μsR0
,
βs
μeR0
(R0 −1),
μs
k
(R0 −1)
 
(15)
which is the equilibrium state corresponding to the endemic
patient, if and only if R0 > 1.
Theorem 2. Assuming that μe ≥ μs:
(i) if R0 ≤ 1, then I0 is the only equilibrium state in Ω,
(ii) if R0 > 1, then the system (5) has two equilibrium
points in Ω: The trivial I0 a n dt h ee n d e m i c a l l yi n f e c t e d
state I1.
Proof. Obviously if R0 = 1 then I1 reduces to I0. And if
R0 < 1, then I1 / ∈Ω. So that I0 is the only one equilibrium
stateinΩ.N o w ,ifμe = μs thenH∗
s +H∗
e = HM,andifμe >μ s
then0 <μ s/μe < 1,andconsequentlywehaveH∗
s +H∗
e <H M.
In any case, H∗
s + H∗
e ≤ HM. So, since VM = (p/μV)HM and
R0 > 1, it follow that V∗ <V M.
4.2.StabilityAnalysisforEquilibriumStates. Inthefollowing,
we study the stability properties of the equilibrium states
corresponding to the healthy individual and the endemically
infected patient.
4.2.1. Stability of I0. The local stability of the equilibrium
state I0 is determined by the eigenvalues of the matrix
J(I0) =
⎛
⎜ ⎜ ⎜ ⎜ ⎜ ⎜ ⎜
⎝
−μs 0 −k
βs
μs
0 −μe k
βs
μs
0 p −μV
⎞
⎟ ⎟ ⎟ ⎟ ⎟ ⎟ ⎟
⎠
(16)
which directly shows that I0 is locally asymptotically stable if
and only if R0 < 1.
To prove that I0 is globally asymptotically stable in Ω,
for R0 ≤ 1, we use the next La Salle’s theorem [22]: ifComputational and Mathematical Methods in Medicine 5
f : Ω → Rn is continuous and locally Lipschitz, Ω ∈ Rn
open, and if U : Ω → R is such that U ∈ C1(Ω), U ≥ 0i nΩ
and its derivative ˙ U ≤ 0 along solution paths of ˙ y = f (y)i n
Ω; then the set ω-limit, if it exists, of every solution path of
˙ y = f(y) is contained in the set Ω0 ={y ∈ Ω : ˙ U(y) = 0}.
Now, as in [11], we consider for system (5) the following
Lyapunov-La Salle function U : Ω → R+,g i v e nb y
U(Hs,He,V) = pHe +μeV. (17)
It is clear that U ∈ C1(Ω)a n dU(Hs,He,V) ≥ 0, for every
(Hs,He,V) ∈ Ω. And it is directly seen that, if R0 ≤ 1, the
derivative of U is non negative along the solution paths of
system (5)i nΩ. So, by La Salle’s theorem, the ω-limit set for
every solution path of system (5) with initial conditions in
int(Ω)i sas u b s e to f
Ω0 =
 
(Hs,He,V) ∈ Ω : ˙ U(Hs,He,V) = 0
 
. (18)
Aﬃrmation. IfR0 ≤ 1,everysolutionpathofsystem(5)with
initialconditionsinΩ0 convergesasymptoticallytothetrivial
equilibrium state I0.
The following has been proved.
Theorem 3. If μe ≥ μs and R0 ≤ 1, then I0 is Ω-globally as-
ymptotically equilibrium state.
4.2.2. Stability of I1. The Jacobian matrix of the endemically
infected equilibrium state I1 is
J(I1) =
⎛
⎜ ⎜ ⎜ ⎜ ⎜ ⎜ ⎜
⎝
−μsR0 0 −
kβs
μsR0
μs(R0 −1) −μe
kβs
μsR0
0 p −μV
⎞
⎟ ⎟ ⎟ ⎟ ⎟ ⎟ ⎟
⎠
(19)
and its associated characteristic polynomial is
p(λ) = λ3 +(a+b)λ2 +abλ+c (20)
with
a = μsR0 > 0,
b = μe +μV > 0,
c = μeμsμV(R0 −1).
(21)
Using the Routh-Hurwitz criterion [23], the local stabil-
ity of the endemic equilibrium I1 is established. In fact, note
that
Δ1 = det(a+b) = a+b>0,
Δ2 = det
⎛
⎝
a+b 1
ca b
⎞
⎠ = (a +b)ab −c,
Δ3 = det
⎛
⎜ ⎜
⎝
a+b 10
ca b a +b
00c
⎞
⎟ ⎟
⎠ = cΔ2 > 0.
(22)
From (21), if R0 > 1 then c>0. Furthermore, we also
have that
Δ2 =
 
μsR0 +μe +μV
 
μsR0
 
μe +μV
 
− μeμsμV(R0 −1)
=
 
μsR0 +μe
  
μe +μV
 
μsR0 +μsμ2
VR0 +μeμsμV > 0.
(23)
To prove the global asymptotic stability of I1 in Ω,w e
use again the La Salle’s theorem, which was enunciated in
the preceding subsection. But now, following [24], we start
considering the following Lyapunov-La Salle function U :
Ω → R+:
U(Hs,He,V) = Hs −H
∗
s ln
Hs
H∗
s
+He −H
∗
e ln
He
H∗
e
+
μe
p
 
V −V
∗ ln
V
V∗
 
.
(24)
Clearly U ∈ C1(Ω), and U(Hs,He,V) ≥ 0f o re v e r y
Hs,He,V>0. Furthermore, if R0 > 1, one can check that
˙ U is non-negative in int(Ω) (for details see [24]). Then, by
La Salle’s theorem, the ω-limit set for every solution path of
system (5) with initial conditions in int(Ω)i sas u b s e to f
Ω0 =
 
(Hs,He,V) ∈ int(Ω) : ˙ U(Hs,He,V) = 0
 
=
  
H∗
s ,H∗
e ,V∗  
.
(25)
In conclusion, we have the following.
Theorem4. Assumingthatμe ≥ μs,ifR0 > 1thenI1 isglobally
asymptotically equilibrium state, and I0 is now an hyperbolic
equilibrium state.
5. NumericalComparison betweenthe Models
In this section, the numerical results reported in [11]a r e
compared with corresponding ones given by the reduced
model studied previously in the last section. In this compar-
ison we use the same initial condition and parameter values
used in [9, 11, 18, 25, 26]. Other numerical simulations
have been carried out and reported in [25–27]. In relation
with initial populations, it is well known that HM =
5000cells/mm3 is mean hepatocyte population for a healthy
individual, that it is reasonable to consider that 10% of
hepatic cells are initially infected, so Hs0 = 4500cells/mm3,
and He0 = 500cells/mm3.A n dV0 = 400UI/μLa n dT0 =
100cells/mm3 are also reasonable values for a low-infection
case.
The initial conditions are
y0 = (4500,500,400,100). (26)
The admissible parameter vector of the model (1)a r e
taken as
θ =
 
βs,k,μs,μe, p,μV,δ,βT,μT,Tmax
 
. (27)6 Computational and Mathematical Methods in Medicine
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Figure 2: Comparing health hepatocyte populations: cured case
(R0 = 0.6).
Case 1 (cure). To compare numerically the evolution behav-
ior of solutions obtained by both models under discussion,
we use the following parameter values:
θ
∗ =
 
100,3 ×10
−5,2×10
−2,5,100,5,10
−5,
3 ×10−4,2× 10−2,1500
  (28)
over a 200-day period, having that R0 = 0.6. The mortality
per capita rate is given in day−1. Figures 2, 3,a n d4,
show graphically the numerical results. Clearly, the temporal
courses of healthy and infected hepatocytes, and viral load
are practically the same in both models.
Case2(endemicdisease). Inthiscase,weusethesameinitial
conditions (26), and the same parameter vectors θ∗,b u t
now with p = 200, and over a 800-day period. Now, we
have that R0 = 1.2. The results are graphically shown in
Figures 5, 6,a n d7. As it could be observed, there are some
small diﬀerences between the evolution of the each three
populations obtained with both models. However, they have
the same asymptotic behavior.
Resuming, the evolution of the three populations under
analysis are essentially the same for both models. Therefore,
for the main objective of this research (the monitoring
hepatic damage without biopsies), it is enough to consider
the restricted model with only three populations (5).
6. ParameterNumericalEstimationandHepatic
Damage Monitoringwithout LiverBiopsies
In the following, by numerical simulations, we show that is
possible to monitor the hepatic damage without biopsies,
in both the cured and endemic cases. To this goal, it is
indispensable to have a suﬃcient number of viral load
0 1 02 03 04 05 06 0
0
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300
350
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450
500
Days
H
e
Initial population
Original model
Reduced model
Figure 3: Comparing infected hepatocyte populations: cured case
(R0 = 0.6).
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1500
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2500
3000
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4000
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V
Initial virus load
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Reduced model
Figure 4: Comparing the HCV loads when the cure takes place
(R0 = 0.6).
measurements, and a reasonable evaluation of population
initial values. These initial values could be provided, in
principle, by an expert physician.
Numerical estimation of parameters k, μe, p, μV,a n d
of the initial viral load V0, were carried out using DIFF-
PAR, a numerical tool written in MATLAB [28, 29]. And
consequently, the numerical evaluation of the threshold
parameterR0 isdirectlyobtained.Tothispurpose,numerical
viral loads are generated by solving numerically the model
(5) for a 30-day period, for a given parameter vector θ
and initial conditions. At 10% normal distributed noise
simulating measurement errors are added to this data. Next,
two circumstances are presented.Computational and Mathematical Methods in Medicine 7
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Figure 5: Comparing health hepatocyte evolutions: endemic case
(R0 = 1.2).
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Figure 6: Comparing sicks hepatocyte evolutions: endemic case
(R0 = 1.2).
(1) Initial conditions are known exactly for all the
variables.
(2) The exact initial value is known only for Hs0 = 4500,
andHe0 = 500.Inthiscase,a10%normaldistributed
noise is added to the initial load V0. Then parameters
and initial viral load are estimated.
The parameter estimation and initial conditions are
determined applying the classical least square criterion, or
thus, minimizing with respect to θ and η the objective
function
g
 
θ,η
 
=
1
2
m  
i=0
wi
 
Vi − V
 
ti;t0,η,θ
  2, (29)
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Figure 7: Comparing HCV loads: endemic case (R0 = 1.2).
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Figure 8: Cured case: comparing the health hepatocyte popula-
tions, Hs0, He0,a n dV0 are given.
where η = V0, θ = (k,μe, p,μV), and V(t;t0,η,θ) is the
solution for viral load in reduced model (5). The weights wi
were calculated according to the following rules:
wi =
⎧
⎪ ⎪ ⎨
⎪ ⎪ ⎩
1
V2
i
,i f Vi >
√
u,
0, if Vi ≤
√
u,
(30)
whereuistheroundingunitintheIEEEstandardsfordouble
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Figure 9: Cured case: comparing the infected hepatocyte popula-
tions (hepatic damage), Hs0, He0,a n dV0 are given.
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Figure 10: Cured case: comparing the viral loads, Hs0, He0,a n dV0
are given.
6.1. Cured Case. Data was generated using parameters
θ∗ ≡
 
β∗
s ,k∗,μ∗
s ,μ∗
e , p∗,μ
∗
V
 
=
 
100, 3 × 10
−5,2 ×10
−2, 5, 100, 5
  (31)
and initial conditions
y0 ≡ (Hs0,He0,V0) = (4500, 500, 400). (32)
0 50 100 150 200
4000
4200
4400
4600
4800
5000
Days
H
s
3800
Known initial population
Exact population
Estimated population
Figure 11: Cured case: comparing the health hepatocyte popula-
tions, Hs0 and He0 are known.
Table 1: Generated data for cured case (R0 = 0.6).
Viral load (V) Viral load (V)
Time (t)( U I / μL) (UI/μL)
(V0 without noise) (V0 with noise)
0 hours 400 4.0501329 ×102
2h o u r s 3 .1826295 ×103 3.4311542 ×103
4h o u r s 4 .0389101 ×103 4.1913114 ×103
8h o u r s 4 .5737159 ×103 4.4215144 ×103
16 hours 3.0550250 ×103 2.7656531 ×103
24 hours 1.7487986 ×103 1.7521023 ×103
2d a y s 3 .7767239 ×102 3.9899151 ×102
3d a y s 7 .1813740 ×101 9.7917259 ×101
4d a y s 1 .8916925 ×101 2.0639365 ×101
6d a y s 9 .4351220 ×10−1 9.3888612 × 10−1
8d a y s 3 .9986367 ×10−2 4.8010863 × 10−2
10 days 2.0585181 ×10−3 2.4422741 × 10−3
14 days 7.5294784 ×10−6 7.6147111 × 10−6
18 days 1.0916324 ×10−6 1.1957034 × 10−6
Inthiscase,R0 = 0.6.Thedatawasgeneratedusinginitial
viral load V0 with and without noise (see Table 1).
Using only viral load data (V), second column in Table 1,
and initial conditions (32), we estimate the parameters k, μe,
p,a n dμV. The optimization process began with the initial
values for parameters
θ0 =
 
100, 9 ×10−5,2 ×10−2, 2, 70, 10
 
. (33)
Table 2 shows the results obtained using DIFFPAR two
times. The temporal courses of the populations are shown
in Figures 8, 9,a n d10. Observe that in Figures 9 and 10
theoretical and estimated curves are practically the same.Computational and Mathematical Methods in Medicine 9
Table 2: Results when Hs0, He0,a n dV0 are known (R0 = 0.6).
kμ e pμ V R0
θ∗ Exact 3 ×10
−5 5 100 5 0.6
  θ Estimated 5.1354 × 10
−5 6.3993 123.91 6.4062 0.78
Error 71.18% 27.99% 23.91% 28.12% 30.00%
Table 3: Results when Hs0 and He0 are known (R0 = 0.6).
kμ e pμ V V0 R0
θ∗ Exact 3 ×10
−5 5 100 5 400 0.6
  θ Estimated 3.5940 ×10
−5 5.6029 115.46 5.5006 405.17 0.67
Error 19.80% 12.06% 15.46% 10.01% 1.29% 11.7%
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Figure 12: Cured case: comparing the infected hepatocyte popula-
tions, Hs0 and He0 are known.
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Figure 13: Cured case: comparing the viral loads, Hs0,a n dHe0 are
known.
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Figure 14: Endemic case: comparing healthy hepatocyte popula-
tions, Hs0, He0,a n dV0 known.
The 95% conﬁdence interval for each parameter of
Table 2 are given by following inequalities (estimated param-
eters appear in the middle):
5.1345 ×10−5 ≤ 5.1354 ×10−5 ≤ 5.1362 ×10−5,
6.3933 ≤ 6.3993 ≤ 6.4053,
123.90 ≤ 123.91 ≤ 123.93,
6.3999 ≤ 6.4062 ≤ 6.4125.
(34)
In an analogous way, using only viral loads data in
Table 1, to estimate k, μe, p,a n dμV, and initial viral load
V0, the initial values for optimization process was V0 = 700,
and
θ0 =
 
100, 9 ×10−5,2 ×10−2, 2, 70, 10
 
. (35)
The results are presented in Table 3. Health and infected
hepatocyte populations and viral load evolutions are shown10 Computational and Mathematical Methods in Medicine
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Figure 15: Endemic case: comparing infected hepatocyte popula-
tions (hepatic damage) when Hs0, He0,a n dV0 are known.
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Figure 16: Endemic case: comparing viral load evolutions when
Hs0, He0,a n dV0 are known.
inFigures11,12,and13.Theestimated parametersandtheir
95% conﬁdence intervals are
3.5931 × 10−5 ≤ 3.5940 ×10−5 ≤ 3.5949 ×10−5,
5.5961 ≤ 5.6029 ≤ 5.6097,
115.44 ≤ 115.46 ≤ 115.48,
5.4937 ≤ 5.5006 ≤ 5.5076,
404.74 ≤ 405.17 ≤ 405.60.
(36)
6.2. Endemic Case. Here, data was generated using the same
parameter vector θ∗ given in (31), with exception of p∗,
Table 4: Generated data for endemic case (R0 = 1.2).
Viral load (V) Viral load (V)
Time (t)( U I / μL) (UI/μL)
(V0 without noise) (V0 with noise)
0 hours 400 4.1309470 ×102
2h o u r s 6 .1816864 ×103 5.3573206 ×103
4h o u r s 8 .3762150 ×103 7.4186646 ×103
8h o u r s 1 .1150813 ×104 1.0106325 ×104
16 hours 1.1135837 ×104 9.0672355 ×103
24 hours 9.3603986 ×103 1.0211713 ×104
2d a y s 4 .7275936 ×103 4.2850412 ×103
3d a y s 1 .5740823 ×103 1.6224563 ×103
4d a y s 6 .5576300 ×102 6.3646394 ×102
6d a y s 8 .0051038 ×101 7.7100090 ×101
8d a y s 9 .0270927 ×100 1.0311416 ×101
10 days 1.3696024 ×100 1.4188935 ×100
14 days 5.0844301 ×10−2 4.9818506 × 10−2
18 days 2.6024858 ×10−3 3.1927516 × 10−3
22 days 2.0748529 ×10−4 2.2361548 × 10−4
26 days 2.6586162 ×10−5 2.5486597 × 10−5
30 days 5.2690861 ×10−6 7.0851754 × 10−6
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Figure 17: Endemic case: comparing viral data, and estimated viral
load evolution when Hs0, He0,a n dV0 are known.
whose value was 200. Also the same initial conditions (32)
were used. In this case, R0 = 1.2. As previously mentioned,
data was generated using initial viral load V0 with and
without noise (see Table 4). To estimate the parameters, the
optimization process began with the initial values for them
θ0 =
 
100, 9 ×10−5,2 ×10−2, 3, 300, 10
 
(37)
and the results are shown in Table 5. Health and infected
hepatocyte populations and viral load evolutions are shown
in Figures 14, 15, 16,a n d17.Computational and Mathematical Methods in Medicine 11
Table 5: Results when Hs0, He0,a n dV0 are known (R0 = 1.2).
kμ e pμ V R0
θ∗ Exact 3 ×10
−5 5 200 5 1.2
  θ Estimated 2.5954 ×10
−5 5.0867 221.38 5.0563 1.117
Error 13.49% 1.73% 10.69% 1.13% 6.92%
Table 6: Results when Hs0 and He0 are given (R0 = 1.2).
kμ e pμ V V0 R0
θ∗ Exact 3 ×10
−5 5 200 5 400 1.2
  θ Estimated 3.3353 ×10
−5 5.5508 214.62 5.3910 413.68 1.1961
Error 11.2% 11.02% 7.3% 7.8% 3.4% 0.33%
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Figure 18: Endemic case: comparing theoretical, and estimated
healthy hepatocyte populations when Hs0 and He0 are given.
Estimated parameters and its 95% conﬁdence intervals
are the following:
2.5953 × 10
−5 ≤ 2.5954 ×10
−5 ≤ 2.5955 ×10
−5,
5.0848 ≤ 5.0867 ≤ 5.0885,
221.37 ≤ 221.38 ≤ 221.38,
5.0544 ≤ 5.0563 ≤ 5.0581.
(38)
Now, using only viral loads (V), third column in Table 4,
we estimate the parameters k, μe, p,a n dμV, and initial viral
load V0. The initial values for optimization process were
V0 = 700 and
θ0 =
 
100, 10−4,2 × 10−2, 15, 500, 30
 
. (39)
The results are presented in Table 6. Estimated parame-
ters, and its 95% conﬁdence intervals are the following:
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Figure 19: Endemic case: comparing theoretical and estimated
infected hepatocyte populations (hepatic damage) when Hs0 and
He0 are given.
3.3347 ×10
−5 ≤ 3.3353 ×10
−5 ≤ 3.3359 ×10
−5,
5.5423 ≤ 5.5508 ≤ 5.5593,
214.60 ≤ 214.62 ≤ 214.65,
5.3827 ≤ 5.3910 ≤ 5.3993,
412.94 ≤ 413.68 ≤ 414.43.
(40)
Theoretical and estimated health and infected hepato-
cyte, and viral load evolutions are shown in Figures 18, 19,
20,a n d21.
7. Discussion
Firstly, we have shown that qualitative behavior of hepatitis
C disease evolution by using the reduced model of three
populations (healthand infectedhepatocytes,andviral load)
is essentially the same that the obtained by using the original12 Computational and Mathematical Methods in Medicine
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Figure 20: Endemic case: comparing theoretical, and estimated
viral load evolutions when Hs0 and He0 are given.
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Figure 21: Endemic case: comparing viral data and estimated viral
load evolution when Hs0 and He0 are given.
model proposed in [11] (Sections 3 and 4). Although, some
diﬀerences are observed in the endemic case, they have
eventually the same behavior (Section 5).
As second conclusion, we have that theoretical and
estimated disease evolutions of cured cases by using the
reduced model, eventually will be observed practically the
same behavior. Even though, in the endemic case some evo-
lution diﬀerences could be noted, the threshold parameter
estimation is good enough.
The third one is our main conclusion. This consists in to
showing that, with the reduced model help and carrying out
numerical simulations, it is completely feasible to warrant
the hepatic damage monitoring without biopsies, under the
a s s u m p t i o nt h a tw eh a v es u ﬃcient number of viral load
measurements (from a statistical point of view, to have two
or three viral loads measurements per each parameter to be
estimated, in our case, from 10 to 15), and reasonable good
initial estimation of the amount of hepatic tissue damaged,
supplied by an expert clinician and hepatopathologist. It is
very important to say that this monitoring procedure does
not have any inconvenience (reliability, complication risks,
patient pain, and other negative aspects), as occurs with con-
ventional biopsies. Even when today percutaneous biopsy for
diagnosing hepatic damage is not so important, the hepatic
damage monitoring is a worthy tool in addition to the viral
load, making possible a good followup. So, even we have not
yetanyexperimentalresearchwithpatientsinordertomodel
calibration and validation, our proposal for monitoring viral
load and hepatic damage evolution (Section 6) represents an
innovative new, worthy, and reliable tool to carry out for
hepatitis C disease tracking, taking account of genotypes and
ethnic considerations [3]. This fact provides a theoretical
foundation to the protocol nowadays used for hepatitis C
treatment without biopsies.
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